Shoes, footwears and deceptive similarity in Trademark law

Shoes, footwears and deceptive similarity in Trademark law Featured image for article: Shoes, footwears and deceptive similarity in Trademark law

The Delhi High Court granted a permanent injunction in favor of New Balance Athletics, Inc., restraining Kiran Shoe Company from infringing its trademarks. The Court awarded ₹7,00,000 in damages and costs, emphasizing that the defendant’s actions were deliberate and aimed at leveraging New Balance’s reputation.

Read more about Shoes, footwears and deceptive similarity in Trademark law

Evaluation of Technical Advancement and Compliance with CRI Guidelines under Indian Patent Law

Evaluation of Technical Advancement and Compliance with CRI Guidelines under Indian Patent Law Featured image for article: Evaluation of Technical Advancement and Compliance with CRI Guidelines under Indian Patent Law

The Madras High Court allowed Idemia Identity & Security France’s appeal, setting aside a refusal order under Section 3(k) for a cryptography patent. The Court ruled the order as a non-speaking one and in violation of natural justice. It directed fresh consideration of the matter, emphasizing technical contributions and adherence to CRI and European guidelines.

Read more about Evaluation of Technical Advancement and Compliance with CRI Guidelines under Indian Patent Law

Court reiterates importance of protecting consumers from confusion in case of pharma products

Court reiterates importance of protecting consumers from confusion in case of pharma products Featured image for article: Court reiterates importance of protecting consumers from confusion in case of pharma products

The Delhi High Court deliberated a trademark infringement case between Modi MundiPharma and Win Health Pharma. Allegations of deceptively similar trademarks in pharmaceutical products were raised, with the Court emphasizing the risk of consumer confusion. The application to challenge the validity of the defendant’s marks was disposed of, framing key issues on the marks’ invalidity.

Read more about Court reiterates importance of protecting consumers from confusion in case of pharma products

“ACTIV” Trademark watch by CASTROL leads to win against deceptively similar mark

The Delhi High Court granted Castrol Limited a permanent injunction and damages for trademark and copyright infringement against defendants marketing deceptively similar lubricants. The judgment highlights the significance of protecting established trademarks and the legal remedies available in Indian courts.

Read more about “ACTIV” Trademark watch by CASTROL leads to win against deceptively similar mark

Indian Patent and Design Statistics 2024 (December 13th to 20th)

This weekly report analyses Indian patent and design statistics for December 13th to 20th, 2024, highlighting key data trends and city-wise breakdowns. It offers insights into patent publications, grants, examinations, and industrial design registrations, compiled by BananaIP’s expert team.

Read more about Indian Patent and Design Statistics 2024 (December 13th to 20th)

Cannot drive on ‘VOLVO’ and ‘FMX’ marks’ reputation rules court

The Delhi High Court has upheld the reputation of VOLVO and FMX trademarks, granting an injunction against unauthorised use by Lamina Suspension Products Ltd. The court recognised VOLVO as a well-known mark and enforced a settlement restricting further misuse.

Read more about Cannot drive on ‘VOLVO’ and ‘FMX’ marks’ reputation rules court

Madras HC Overrules Procedural Rejection in France Telecom’s Patent Case

The Madras High Court allowed France Telecom’s writ petition, setting aside the procedural rejection of its patent application examination request. The judgment clarifies the treatment of agent errors under Indian patent law and upholds procedural fairness.

Read more about Madras HC Overrules Procedural Rejection in France Telecom’s Patent Case

Revisiting Novartis versus Natco – Cancer drugs, divisional applications and patent validity

The Delhi High Court upheld the validity of Novartis’s Ceritinib patent against Natco’s challenge, addressing divisional application issues and allegations of suppression. The injunction against Natco remains in force, reinforcing the enforceability of Novartis’s patent rights.

Read more about Revisiting Novartis versus Natco – Cancer drugs, divisional applications and patent validity